All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage M0/M1A/M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - 1st line (L1), nivolumab alone vs. ipilimumab based treatment, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
0.63 [0.48 ; 0.82 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 631 NA not evaluable deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
0.63 [0.52 ; 0.76 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 631 NA not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
0.53 [0.44 ; 0.64 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 631 NA not evaluable progression or deaths (PFS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
0.57 [0.43 ; 0.76 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 631 NA not evaluable objective responses (ORR)detailed results CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
3.40 [2.02 ; 5.72 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 631 NA not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
3.54 [2.46 ; 5.10 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 631 NA not evaluable TRAE (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
1.01 [0.64 ; 1.59 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
0.71 [0.49 ; 1.03 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
0.99 [0.02 ; 50.24 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
0.72 [0.45 ; 1.13 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
0.52 [0.31 ; 0.88 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
0.25 [0.01 ; 5.50 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
1.99 [0.18 ; 22.10 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
1.99 [0.07 ; 59.55 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
0.50 [0.04 ; 5.49 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
0.12 [0.03 ; 0.39 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
3.99 [0.18 ; 88.92 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
0.50 [0.02 ; 14.84 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
0.48 [0.21 ; 1.09 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
0.99 [0.02 ; 50.24 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
1.99 [0.07 ; 59.55 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
0.99 [0.20 ; 4.96 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
0.50 [0.02 ; 14.84 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
0.99 [0.02 ; 50.24 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
0.99 [0.02 ; 50.24 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
0.20 [0.02 ; 1.69 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
0.99 [0.02 ; 50.24 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
1.50 [0.25 ; 9.01 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
0.79 [0.21 ; 2.98 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
1.17 [0.53 ; 2.56 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
1.99 [0.18 ; 22.10 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
1.99 [0.07 ; 59.55 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
0.25 [0.01 ; 5.50 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
0.99 [0.06 ; 15.96 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
0.99 [0.02 ; 50.24 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
0.99 [0.06 ; 15.96 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
0.50 [0.02 ; 14.84 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
0.20 [0.02 ; 1.69 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
0.99 [0.02 ; 50.24 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
1.99 [0.07 ; 59.55 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
0.99 [0.06 ; 15.96 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
0.50 [0.02 ; 14.84 ] CheckMate 067 (N vs I ; all population), 2015 1 0% 624 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 07:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 285,68,127,128
- treatments: 360,719,721,720